GlassScriptPhysician profile
James M Jung
NPI 1912920919
$10,648.35
in general payments reported to CMS, 2019-2025
51 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,224 · 2020: $1,396 · 2021: $1,953 · 2022: $1,306 · 2023: $1,418 · 2024: $1,309 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,728 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,728.00 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,287.51 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $999.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $914.03 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $734.25 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Ironwood Pharmaceuticals, INC | $712.13 | 2019-2024 | Linzess |
| Novartis Pharmaceuticals Corporation | $676.98 | 2019-2024 | |
| Stryker Corporation | $491.00 | 2019 | |
| Merck Sharp & Dohme LLC | $455.52 | 2019-2025 | Verquvo, Belsomra |
| Gilead Sciences, INC. | $446.96 | 2020-2025 | |
| Lilly USA, LLC | $307.72 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amarin Pharma, INC. | $306.71 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.00 | 2023-2024 | Xifaxan |
| Ardelyx, INC. | $244.79 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $227.19 | 2023-2025 | Shingrix, Arexvy |
| Eisai INC. | $223.88 | 2021-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.